<DOC>
	<DOCNO>NCT00862758</DOCNO>
	<brief_summary>Application Compassionate Use Tocilizumab Boy Severe Polyarticular Juvenile Idiopathic Arthritis ( JIA ) Unresponsive All Licensed Medications .</brief_summary>
	<brief_title>Request Single Patient IND Compassionate/Emergency Use Tocilizumab</brief_title>
	<detailed_description>This trial single subject juvenile idiopathic arthritis unresponsive license treatment JIA , license rheumatoid arthritis . He currently wheelchair bound completely dependent activity daily live self-care . He constant pain , abundant warmth swell nearly joint include TMJs , neck , shoulder , elbow , wrist , MCP finger joint ( even DIP joint ) , hip , knee , ankle , subtalar intertarsal joint , MTP IP joint toe . Drug dose 8 mg/kg would administer IV every 2 week , close safety monitoring study . Treatment would monitor every 2 week . Efficacy measure use ACR Pedi 30 , 50 90 definition previously publish , base : 1 ) physician global assessment disease activity ; 2 ) parent/patient assessment overall well-being ; 3 ) functional ability ; 4 ) number joint active arthritis ; 5 ) number joint limit range motion ; 6 ) erythrocyte sedimentation rate .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Emergencies</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<criteria>Subject X , polyarticular JIA , respond drug Not identify subject</criteria>
	<gender>Male</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>juvenile idiopathic arthritis</keyword>
</DOC>